Remdesivir has reported efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and in vivo. Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In intensive care unit (ICU) settings, in which multiple-organ dysfunctions can occur rapidly, hemodialysis may be a viable option for maintaining remdesivir treatment, while improving tolerance, by removing both remdesivir’s metabolite (GS-441524) and sulfobutylether β-cyclodextrin sodium (SEBCD). Additional studies may prove informative, particularly in the evaluations of therapeutic options for coronavirus disease 2019 (COVID-19).

中文翻译：

---

在COVID-19的双肺移植受者中通过血液透析去除remdesivir的代谢产物GS-441524。

Remdesivir已报道在体外和体内对严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）的疗效。药物相互作用限制了移植患者的治疗选择。雷姆昔韦及其代谢产物GS-441524主要从尿中排出。在重症监护病房（ICU）可能会迅速发生多器官功能障碍的环境中，血液透析可能是通过去除瑞姆昔韦的代谢产物（GS-441524）和磺基丁基醚β-环糊精钠来维持瑞姆昔韦治疗并提高耐受性的可行选择（SEBCD）。额外的研究可能证明是有益的，尤其是在评估2019年冠状病毒病（COVID-19）的治疗选择方面。